Acute kidney injury

Acute kidney injury (AKI) – an abrupt deterioration in renal function – causes a rise in serum creatinine (SCr) or fall in urine output. It is common, occurring in up to 20% of hospital admissions. Importantly, even small rises in SCr are associated with increased risk of death and longer hospital stays. A 2009 National Confidential Enquiry into Patient Outcome and Death report found that a proportion of AKI in secondary care was avoidable. In addition, management of established AKI was ‘good’ less than half the time. In practice, AKI represents a heterogeneous group of conditions, encompassing impairments in both kidney structure and function. Delivering disease-specific treatment early in the course of AKI may improve outcomes. The provision of best-practice care for all will rely on a better understanding of risk, and frameworks of care that can be applied across a diverse patient group.

Introduction – definitions and importance

Acute kidney injury (AKI) – an abrupt deterioration in renal function – causes a rise in serum creatinine (SCr) or fall in urine output. The magnitude of these changes is used to stratify the severity of AKI, as defined in an internationally agreed system of classification designed for clinical practice and research (KDIGO).1 Using this classification, AKI is common, occurring in up to 20% of hospital admissions.2 Importantly, even small rises in SCr are independently associated with an increased risk of death.2 Some 40,000 excess deaths are attributed to AKI each year in England alone;3 a mortality burden greater than that attributable to MRSA and venous thromboembolism combined.4 Morbidity is also high in AKI; it is associated with an increased length of stay,1 and the development of chronic kidney disease.5 This is expensive; one recent economic analysis estimated the associated healthcare costs for England alone to be over £1 billion per annum; a yearly cost that exceeds treatment for some major cancers.5

In practice, AKI represents a heterogeneous group of conditions, encompassing impairments in kidney structure and function. Of those diagnosed with AKI in hospital, roughly half will have effective hypovolaemia or sepsis.6 The remaining cases are caused by a mixture of obstructive uropathy, nephrotoxins and a variety of parenchymal renal diseases. The London AKI Network has produced comprehensive guidelines and care pathways, designed to assist clinicians in routine management. Their summary of the main causes of AKI is shown in Box 1.

Understanding risk in AKI

A 2009 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report found that the care of patients with established AKI was ‘good’ less than half the time.7 The potential for the reduction of patient morbidity, mortality and healthcare costs in AKI are thus clear. Alongside sepsis, the NHS

Box 1. The primary causes of AKI. Reproduced with permission from the London AKI Network.

Sepsis and hypoperfusion:
> severe sepsis
> haemorrhage
> dehydration
> cardiac failure
> liver failure
> renovascular insult (eg aortic surgery).

Toxicity:
> nephrotoxic drugs
> iodinated radiological contrast.

Obstruction:
> bladder outflow
> stones
> tumour
> surgical ligation of ureters
> extrinsic compression (eg lymph nodes)
> retroperitoneal fibrosis.

Parenchymal kidney disease:
> glomerulonephritis
> tubulointerstitial nephritis
> rhabdomyolysis
> haemolytic uraemic syndrome
> myeloma kidney
> malignant hypertension.
AKI Care Bundle

Institute in all patients with a 1.5X rise in creatinine or oliguria (>0.5 mL/kg/h) for >6 h

This is a medical emergency

Full set of physiological observations; assess for signs of shock/hypoperfusion; if MEWS triggering give oxygen, begin resuscitation and contact critical care outreach team

Fluid therapy in AKI

- Assess heart rate, blood pressure, jugular venous pressure, capillary refill (should be <3 sec), conscious level.
- If hypovolaemic give bolus fluids (eg 250–500 mL) until volume replete with regular review of response.
- Middle grade review if >2 L filling in oliguria.
- If the patient is euvoalaemic give maintenance fluids (estimated output plus 500 mL) and set daily fluid target.

Monitoring in AKI

- Do arterial blood gas and lactate if venous bicarbonate is low or evidence of severe sepsis or hypoperfusion.
- Consider insertion of urinary catheter and measurement of hourly urine volumes.
- Measure urea, creatinine, bone, other electrolytes and venous bicarbonate at least daily while creatinine rising.
- Measure daily weights, keep a fluid chart and perform a minimum of 4 hourly observations.
- Perform regular fluid assessments and check for signs of uraemia.

Investigation of AKI

- Investigate the cause of all AKI unless multi-organ failure or obvious precipitant
- Urine dipstick: if proteinuria is present perform urgent spot urine PCR.
- USS should be performed within 24 h unless AKI cause is obvious or AKI is recovering or within 6 hours if obstruction with infection (pyonephrosis) is suspected.
- Check liver function (hepatorenal), CRP and CK (rhabdomyolysis); if platelets low do blood film/LDH/Bili/retics (HUS/TTP). If PCR high, consider urgent Bence Jones protein and serum free light chains.

Supportive AKI care

- Treat sepsis - in severe sepsis intravenous antibiotics should be administered within 1 hour of recognition.
- Stop NSAID/ACE/ARB/metformin/K-sparing diuretics and review all drug dosages.
- Give proton pump inhibitor and perform dietic assessment.
- Stop anti-hypertensives if relative hypotension. If hypovolaemic consider stopping diuretics.
- Avoid radiological contrast if possible. If given follow prophylaxis protocol.

Causes think ‘STOP AKI’
Sepsis and hypoperfusion, toxicity (drugs/contrast), obstruction, parenchymal kidney disease (acute GN)

Fig 1. An AKI care bundle.

Reproduced with permission from the London AKI Network. ACE = angiotensin-converting-enzyme; AKI = acute kidney injury; ARB = angiotensin-receptor blocker; Bili = bilirubin; CK = creatine kinase; CRP = C-reactive protein; HUS = hemolytic-uremic syndrome; LDH = lactate dehydrogenase; NSAIDs = non-steroidal anti-inflammatory drugs; PCR = protein-creatinine ratio; retics = reticulocytes; TTP = thrombotic thrombocytopenic purpura.

Five year forward view identified improving AKI care as an area that will maximally reduce avoidable mortality. Improving outcomes at scale will depend on better understanding of risk, and the consistent delivery of best-practice care. The 2009 NCEPOD report also highlighted that up to 20% of AKI in secondary care was avoidable. The chance of developing AKI following exposure to an insult depends on a host of individual factors. These relate to both underlying susceptibilities (eg existing chronic kidney disease or diabetes) and exposures in hospital (eg sepsis or major surgery). Care should be taken to ensure that these exposures are minimised for patients at risk; this will include ensuring volume status is optimised and the avoidance of nephrotoxins. Monitoring of serum creatinine and urine output is also important for early recognition of AKI; but it should also be borne in mind that rises in Scr will lag behind any drops in glomerular filtration rate following an insult to the kidneys by several days.

An organised approach to patient management

While the relationship between AKI, critical illness and comorbidities is complex, there is broad recognition that a
strategy of early intervention may avoid significant parenchymal injury in patients with multi-system illness.10,11 Early review by a nephrology team may help ameliorate AKI,12 but the numbers of patients developing AKI and the centralisation of services make this impossible for all. As a result, local and regional care protocols exist for monitoring, investigation and supportive care (see Fig 1 for an example of such a pathway).13

Managing complications and tertiary referral

Patients with established AKI must also be monitored for complications; some may need to be cared for in higher acuity areas of care. Care protocols can guide immediate management and ensure patient safety (see Fig 2).

In addition, for any AKI patient with one of the above complications, local critical care services should be contacted for patients with AKI (serum creatinine >3X baseline OR >354 µmol/L OR initiation of renal replacement therapy), or those in whom imminent recovery is unlikely. Urgent referral to local urological services is warranted for those with obstruction on ultrasound. In the first instance, referrals to local nephrology services should be reserved for patients with AKI and the following:

- myeloma
- suspected autoimmune disease or glomerulonephritis (positive autoimmune screen; blood or protein on urine dip)
- suspected hemolytic–uremic syndrome and thrombotic (history of diarrhoea or rash)
- thrombocytopenic purpura
- suspected poisoning.

Future frameworks for care

Recent local and national initiatives have focused on early recognition and timely intervention, leading to the adoption

---

**AKI Complications**

**Hyperkalaemia, acidosis, pulmonary oedema, reduced conscious level**

**Begin medical therapy and get help**

**Local critical care team and local nephrology team (if onsite)**

**Hyperkalaemia**

- Medical therapy of hyperkalaemia is a transient measure pending imminent recovery in renal function or transfer to kidney unit or critical care for renal replacement therapy.
- If ECG changes give calcium gluconate 10 mL 10%.
- If bicarbonate <2 mmol/L and no fluid overload give 500 mL 1.26% sodium bicarbonate over 1 h.
- K >6.5 mmol/L or ECG changes give insulin 10 IU in 50 mL of 50% dextrose over 15 min and salbutamol 10 mg nebulised (caution with salbutamol in tachycardia or ischaemic heart disease).
- Insulin/dextrose and salbutamol reduce ECF potassium for <4 h only.

**Acidosis**

- Medical therapy of acidosis with bicarbonate should be reserved for emergency management of hyperkalaemia (as above) pending specialist help.
- pH <7.15 requires immediate critical care referral.

**Pulmonary oedema**

- Sit the patient up and give oxygen (60–100% unless contraindicated).
- If haemodynamically stable give furosemide 80 mg iv. Consider repeat bolus and infusion at 10 mg/h.
- If haemodynamically stable commence GTN 1–10 mg/h titrating dose.

**Reduced conscious level**

- Manage uremic coma as per all reduced consciousness (airway management) pending critical care transfer and emergency renal replacement therapy.

**These are holding measures prior to specialist help from critical care or nephrology services.**

---

Fig 2. Managing complications in AKI. Reproduced with permission from the London AKI Network. AKI = acute kidney injury; ECG = echocardiogram; ECF = extracellular fluid; GTN = glyceryl trinitrate.
of real-time automated diagnostic algorithms.14 NHS England have produced one such algorithm, mandating that it be incorporated in some way into all hospital laboratory information management systems. Alerts for patients with AKI are to be displayed in patient management systems and reported centrally.15 However, trials of automated clinical decision support tools have had mixed results. A recent randomised controlled trial testing the efficacy of simple electronic e-alerting for AKI resulted in no significant differences in patient peak creatinine, requirement for dialysis or risk of death.16 As discussed above, patients with AKI form a heterogeneous group, and therapy is not standardised; a new process may be needed to guide the nature and scale of clinical response in the right timeframe. It has already been demonstrated that existing patient data can be used to reduce false positive alerts (eg patients with chronic kidney disease or on renal replacement therapy).17 As computers become more powerful and patient-specific data are coded with greater granularity, the potential for more advanced risk prediction using artificial intelligence is huge. Current approaches in the diagnosis of AKI are also limited by the regularity with which SCr or urine output are measured. In the future, strategies may focus on fostering early detection and more targeted therapy. Numerous novel biomarkers reflecting function or structural damage to the kidney have been investigated (neutrophil gelatinase-associated lipocalin, kidney injury molecule 1). Although there is hope that they may one day facilitate earlier diagnosis or differentiate separate causal pathways, current approaches lack sensitivity and may be less effective at the level of the individual patient. Crucially, they have yet to consistently show value in clinical decision making above and beyond existing SCr and urine output monitoring. Future efforts may focus on their use alongside existing biochemical and clinical information.18

References


Address for correspondence: Dr A Connell, 170 Tottenham Court Road, London W1T 7HA, UK.
Email: alistair.connell@ucl.ac.uk